In summary, GPP could ameliorate NASH possibly mediated via the modulation of gut microbiota and the TLR2/NLRP3 signaling pathway, indicating that GPP could be tested as a prebiotic agent in the prevention of NASH. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatohepatitis.